Pinned Tweet
Excited to share our official launch, featured exclusively in @endpts, by @RLCscienceboss! Hear from our cofounders @AmitDeshwar, @juliapeng__, and Melissa J. Moore on how we're using AI foundation models to create better, more durable mRNAs - and open up new therapeutic frontiers.
endpts.com/modernas-former-t…
How will AI change the way we design genetic medicines?
Our co-founder Melissa J. Moore will be speaking at @endpts AI Day on Oct 14! Join her in exploring how next-generation foundation models will help scale custom medicines.
NYC + virtual
events.endpoints.news/aiday2…
AI is rapidly expanding the supply of therapeutic ideas, but turning them into effective medicines is still hard.
In our new essay, our co-founder Melissa J. Moore explores how better mRNAs can unlock novel medicines, and why mRNA’s most important chapter is still ahead.
kernalabs.substack.com/p/mrn…
The bottleneck for mRNA is producing more protein in the right cell types, with a longer duration. Better mRNA sequence design is the key to making previously impractical therapies possible – and expand the range of diseases we can treat.
Moderna just showed what mRNA can do beyond vaccines: its individualized cancer therapy, with Keytruda, succeeded in Ph3.
When LLMs began rapidly progressing 3y ago, we made a bet that AI models can outperform human-led design to create better mRNAs. 🧵1/4
Models are only as good as their data. Public RNA datasets weren't built for therapeutic, chemically-modified mRNA.
So we built a high-throughput data engine to generate protein-level measurements in vivo. With this engine, our designs have improved 6x over the past year. 3/4
Kerna Labs retweeted
Cancer vaccines coming… LFG!
GOLDEN AGE OF INTELLIGENCE AND PROBLEM SOLVING 🧠 🚀
WHAT A TIME TO BE ALIVE!!!
Positive results from a skin cancer vaccine trial are boosting $MRK and $MRNA shares.
Moderna's CEO and the President of Merck Research Laboratories share their thoughts on the encouraging data. cnb.cx/4y9CSmn
We started Kerna on the thesis that mRNA would become a widespread therapeutic modality beyond vaccines. Today, Moderna’s mRNA cancer therapy + Keytruda met its Ph3 endpoints.
We’re already building the foundation models and in vivo data engine for what comes next.
We're hiring summer fellows for a unique, high-impact role! Looking for sharp biology minds to dive into disease mechanisms and explore how mRNA can unlock new therapies. Reach out to [email protected]
Excited for the @KernaLabs Summer Fellowship for rising Seniors & new graduates looking to dive into the frontier of AI & RNA therapeutic design.
Proud to be building with @AmitDeshwar, @juliapeng__, Melissa J. Moore, @MichaelSwi86721, and Oliver Chang.
Grateful for the support from @GradientVC, @humbavc, @tauventures, @focalpointlp, @HF0Residency, @pdhsu, @jacobkimmel, and many more!
kernalabs.ai